Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lipocine's change in working capital for the quarter that ended in Jun. 2026 was $-0.41 Mil.
Lipocine's change in working capital for the fiscal year that ended in Dec. 2025 was $-0.24 Mil.
It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).
Lipocine Change In Working Capital Historical Data
* Premium members only.
The historical data trend for Lipocine's Change In Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.63 Mil.
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.
Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net
(566)
(614)
(796)
Inventories
(1,667)
(2,759)
(3,727)
Accounts payable
531
1,061
2,687
Accrued liabilities
103
271
(935)
Accrued income taxes
(1,224)
981
994
For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Working Capital of $0.63 Mil mean?
Lipocine (LPCN) has a Change In Working Capital of $0.63 Mil as of Jun. 2026. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for Lipocine.
Is Lipocine's Change In Working Capital too high?
Lipocine's current Change In Working Capital is $0.63 Mil. Overall, Lipocine has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lipocine's Change In Working Capital compare to TPST and CYCN?
Lipocine's Change In Working Capital of $0.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Working Capital for a Biotechnology company?
A good Change In Working Capital depends on the Biotechnology industry context. However, Change In Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Working Capital mean?
A high Change In Working Capital can signal that a stock is expensive relative to its fundamentals. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for Lipocine. Lipocine's current Change In Working Capital is $0.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Based on GuruFocus' analysis, Lipocine (LPCN) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.33, compared to a current price of $2.45 — trading 84.2% above its estimated fair value. The current Change In Working Capital is $0.63 Mil. Lipocine's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Working Capital calculated?
Change In Working Capital is calculated from a company's financial statements. For Lipocine (LPCN), the current Change In Working Capital is $0.63 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lipocine (LPCN) Overvalued in 2026?
Based on GuruFocus' analysis, Lipocine stock appears to be overvalued.
The current stock price of $2.45 is trading 84.2% above its estimated GF Value™ of $1.33.
GuruFocus considers Lipocine to be Significantly Overvalued.
Key valuation signals for LPCN:
Change In Working Capital: $0.63 Mil
GF Value™: $1.33 vs. price of $2.45 (84.2% above fair value)
No single metric tells the full story. See the LPCN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
42GF Score
Get the complete analysis for LPCN
Change In Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LPCN has been successfully added to your 
